

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Terms	Documents
16 and 110	5

Database:

US Patents Full-Text Database	▲
JPO Abstracts Database	
EPO Abstracts Database	
Derwent World Patents Index	
IBM Technical Disclosure Bulletins	▼

Refine Search:

16 and 110

[Clear](#)**Search History****Today's Date: 9/25/2000**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	16 and 110	5	L11
USPT	genetic near3 vaccine	198	L10
USPT	16 and 18	0	L9
USPT	cell near3 specifc	1	L8
USPT	cell-specific	0	L7
USPT	14 and 15	324	L6
USPT	11 and 13	984	L5
USPT	receptor near3 binding	13678	L4
USPT	12 near3 binding	7742	L3
USPT	(nucleic adj acid) or dna	45925	L2
USPT	vaccine	9987	L1

WEST

Generate Collection

Search Results - Record(s) 1 through 5 of 5 returned.☐ 1. Document ID: US 6072048 A

L11: Entry 1 of 5

File: USPT

Jun 6, 2000

US-PAT-NO: 6072048

DOCUMENT-IDENTIFIER: US 6072048 A

TITLE: DNA molecule encoding for cellular uptake of Mycobacterium tuberculosis and uses thereof

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 2. Document ID: US 6008201 A

L11: Entry 2 of 5

File: USPT

Dec 28, 1999

US-PAT-NO: 6008201

DOCUMENT-IDENTIFIER: US 6008201 A

TITLE: DNA molecule encoding for cellular uptake of mycobacterium tuberculosis and uses thereof

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 3. Document ID: US 5861290 A

L11: Entry 3 of 5

File: USPT

Jan 19, 1999

US-PAT-NO: 5861290

DOCUMENT-IDENTIFIER: US 5861290 A

TITLE: Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 4. Document ID: US 5837533 A

L11: Entry 4 of 5

File: USPT

Nov 17, 1998

US-PAT-NO: 5837533

DOCUMENT-IDENTIFIER: US 5837533 A

TITLE: Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 5. Document ID: US 5837510 A

L11: Entry 5 of 5

File: USPT

Nov 17, 1998

US-PAT-NO: 5837510

DOCUMENT-IDENTIFIER: US 5837510 A

TITLE: Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

Generate Collection

Terms	Documents
16 and 110	5

Display

20

Documents, starting with Document:

5

Display Format:

TI

Change Format

=> d his

(FILE 'HOME' ENTERED AT 17:38:31 ON 25 SEP 2000)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 17:38:44 ON 25 SEP 2000

L1 220 S GENETIC(W)VACCINE
L2 2152 S GENETIC(5A)VACCINE
L3 181459 S (NUCLEIC(W)ACID OR DNA) (3A)BINDING
L4 186018 S RECEPTOR(3A)BINDING
L5 1 S L2 AND L3 AND L4
L6 1072 S CELL-SPECIFIC(3A)RECEPTOR
L7 1 S L2 AND L3 AND L6

=> d bib ab 17

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2000 ACS

AN 1999:529282 CAPLUS

DN 131:154480

TI Methods for obtaining a cell-specific binding molecule that increases uptake and/or specificity of a **genetic vaccine** to a target cell

IN Punnonen, Juha; Stemmer, Willem P. C.; Howard, Russell; Patten, Phillip A.

PA Maxygen, Inc., USA

SO PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9941402	A2	19990819	WO 1999-US3023	19990210
	WO 9941402	A3	19991111		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,

TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU	9926742	A1	19990830	AU 1999-26742	19990210
PRAI	US 1998-21769		19980211		
	US 1998-74294		19980211		
	WO 1999-US3023		19990210		

AB The present invention provides methods for obtaining a cell-specific binding mol. that is useful for increasing uptake or specificity of a **genetic vaccine** to a target cell. The methods involve (1) creating a library of recombinant polynucleotides encoding polypeptides with a **nucleic acid binding** domain and polypeptides with a cell-specific binding domain; and (2) screening said library for recombinant polynucleotides that encode mols. that can bind to a nucleic acid and also to a **cell-specific receptor**. Specifically, the invention

describes the use of the DNA shuffling method to evolve receptor binding components of enterotoxins derived from *Vibrio cholerae* and enterotoxigenic strains of *E. coli* for improved attachment to cell surface receptors and for improved entry to and transport across the cells of the intestinal epithelium. An antigen of interest can be fused to these toxin subunits to facilitate the screening of evolved enterotoxin subunits, and also to facilitate oral delivery of proteins. The invention also provides methods of evolving a bacteriophage-derived vaccine delivery vehicle to obtain a delivery vehicle having enhanced ability to enter a target cell.

=> d his

(FILE 'HOME' ENTERED AT 17:38:31 ON 25 SEP 2000)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 17:38:44 ON 25 SEP 2000

L1 220 S GENETIC(W)VACCINE
L2 2152 S GENETIC(5A)VACCINE
L3 181459 S (NUCLEIC(W)ACID OR DNA) (3A)BINDING
L4 186018 S RECEPTOR(3A)BINDING
L5 1 S L2 AND L3 AND L4
L6 1072 S CELL-SPECIFIC(3A)RECEPTOR
L7 1 S L2 AND L3 AND L6
L8 223217 S VACCINE
L9 10 S L8 AND L3 AND L4
L10 1 S L3 AND L6 AND L8
L11 10 DUP REM L9 (0 DUPLICATES REMOVED)

=> d 1-10 au ti so l11

L11 ANSWER 1 OF 10 MEDLINE

AU Doffinger R; Jouanguy E; Dupuis S; Fondan`eche M C; Stephan J L; Emile J F; Lamhamedi-Cherradi S; Altare F; Pallier A; Barcenas-Morales G; Meinel E;

Krause C; Pestka S; Schreiber R D; Novelli F; Casanova J L
TI Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guerin and Mycobacterium abscessus infection.
SO JOURNAL OF INFECTIOUS DISEASES, (2000 Jan) 181 (1) 379-84.
Journal code: IH3. ISSN: 0022-1899.

L11 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2000 ACS

IN Punnonen, Juha; Stemmer, Willem P. C.; Howard, Russell; Patten, Phillip A.
TI Methods for obtaining a cell-specific binding molecule that increases uptake and/or specificity of a genetic **vaccine** to a target cell
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2

L11 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2000 ACS

AU Carson, Susan D. Biegel; Klebba, Philip E.; Newton, Salette M. C.; Sparling, P. Frederick
TI Ferric enterobactin binding and utilization by Neisseria gonorrhoeae
SO J. Bacteriol. (1999), 181(9), 2895-2901
CODEN: JOBAAY; ISSN: 0021-9193

L11 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2000 ACS

IN Grandi, Guido
TI Targetting and uptake of DNA by animal cells by receptor-mediated endocytosis using fusion protein of toxins and **DNA-binding** proteins
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2

L11 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2000 ACS

IN King, Dannie H.
TI Nucleic acid composition with ganglioside GM1-binding protein for delivery

to mucosal, neural or other cells, nucleic acid expression, and immunomodulation or gene therapy
SO PCT Int. Appl., pp.
CODEN: PIXXD2

L11 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2000 ACS
IN Tong, Shuping; Li, Jisu; Wands, Jack R.
TI Hepadnavirus receptors and receptor-encoding **nucleic acids, receptor-binding** hepadnaviral pre-S protein fragments, and hepadnavirus **vaccines**
SO PCT Int. Appl., 174 pp.
CODEN: PIXXD2

L11 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2000 ACS
IN Collier, R. John; Eisenberg, David; Fu, Haian; Choe, Seunghyon
TI Diphtheria toxin **receptor-binding** region, and use for **vaccine**
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2

L11 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2000 ACS
IN Bisaccia, Emil; Klainer, Albert S.
TI Photoactive compounds, especially psoralens, and photopheresis in treatment of and **vaccine** production against viral infections, especially AIDS
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2

L11 ANSWER 9 OF 10 MEDLINE
AU Tan J A; Joseph D R; Quarmby V E; Lubahn D B; Sar M; French F S; Wilson E M
TI The rat androgen receptor: primary structure, autoregulation of its messenger ribonucleic acid, and immunocytochemical localization of the receptor protein.
SO MOLECULAR ENDOCRINOLOGY, (1988 Dec) 2 (12) 1276-85.
Journal code: NGZ. ISSN: 0888-8809.

L11 ANSWER 10 OF 10 MEDLINE
AU Wilson E M; Lubahn D B; French F S; Jewell C M; Cidlowski J A
TI Antibodies to steroid **receptor** deoxyribonucleic acid **binding** domains and their reactivity with the human glucocorticoid receptor.
SO MOLECULAR ENDOCRINOLOGY, (1988 Nov) 2 (11) 1018-26.
Journal code: NGZ. ISSN: 0888-8809.

=> d bib 4-8 111

L11 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2000 ACS
AN 1999:27954 CAPLUS
DN 130:77075
TI Targetting and uptake of DNA by animal cells by receptor-mediated endocytosis using fusion protein of toxins and **DNA-binding** proteins
IN Grandi, Guido
PA Chiron S.P.A., Italy
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9859065	A1	19981230	WO 1998-IB1005	19980618

W: JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE

PRAI GB 1997-13122 19970620

RE.CNT 6

RE

- (1) Dana Farber Cancer Inst Inc; WO 9522618 A 1995
 - (2) Maxim Pharmaceuticals; WO 9705267 A 1997
 - (3) Miles Inc; WO 9404696 A 1994
 - (4) Starnbach Michael N; WO 9613599 A 1997
 - (5) Starnbach Michel N; WO 9723236 A 1997
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2000 ACS

AN 1997:207764 CAPLUS

DN 126:203696

TI Nucleic acid composition with ganglioside GM1-binding protein for delivery

to mucosal, neural or other cells, nucleic acid expression, and immunomodulation or gene therapy

IN King, Dannie H.

PA Maxim Pharmaceuticals, USA

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9705267	A2	19970213	WO 1996-US12041	19960719
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	AU 9665057	A1	19970226	AU 1996-65057	19960719
	EP 840796	A2	19980513	EP 1996-924664	19960719
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11510164	T2	19990907	JP 1996-507664	19960719
PRAI	US 1995-1527		19950726		
	WO 1996-US12041		19960719		

L11 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2000 ACS

AN 1997:220629 CAPLUS

DN 126:208747

TI Hepadnavirus receptors and receptor-encoding **nucleic acids, receptor-binding** hepadnaviral pre-S protein fragments, and hepadnavirus **vaccines**

IN Tong, Shuping; Li, Jisu; Wands, Jack R.

PA General Hospital Corporation, USA

SO PCT Int. Appl., 174 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9704000	A1	19970206	WO 1996-US12098	19960722
	W: AU, CA, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	US 5929220	A	19990727	US 1996-683262	19960718
	AU 9666792	A1	19970218	AU 1996-66792	19960722
	EP 853629	A1	19980722	EP 1996-926759	19960722
	R: AT, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, PT, IE				
	JP 11510381	T2	19990914	JP 1996-506950	19960722

PRAI US 1995-1371 19950721
WO 1996-US12098 19960722

L11 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2000 ACS

AN 1994:156463 CAPLUS

DN 120:156463

TI Diphtheria toxin **receptor-binding** region, and use for
vaccine

IN Collier, R. John; Eisenberg, David; Fu, Haian; Choe, Seunghyon

PA President and Fellows of Harvard College, USA

SO PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9321769	A1	19931111	WO 1993-US4166	19930503
	W: AU, BB, BG, BR, CA, CZ, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9342304	A1	19931129	AU 1993-42304	19930503
	EP 643559	A1	19950322	EP 1993-911012	19930503
	EP 643559	B1	19990414		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07506821	T2	19950727	JP 1993-519584	19930503
	AT 178907	E	19990415	AT 1993-911012	19930503
	ES 2130265	T3	19990701	ES 1993-911012	19930503
	US 5843711	A	19981201	US 1995-552248	19951102
PRAI	US 1992-881394		19920506		
	WO 1993-US4166		19930503		
	US 1993-119316		19930909		

L11 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2000 ACS

AN 1991:20282 CAPLUS

DN 114:20282

TI Photoactive compounds, especially psoralens, and photopheresis in
treatment of and **vaccine** production against viral infections,
especially AIDS

IN Bisaccia, Emil; Klainer, Albert S.

PA USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9007952	A1	19900726	WO 1990-US275	19900110
	W: AU, BR, DK, ES, FI, HU, JP, NO				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	US 4960408	A	19901002	US 1989-295454	19890110
	IL 92996	A1	19960618	IL 1990-92996	19900108
	CA 2007499	AA	19900710	CA 1990-2007499	19900110
	AU 9049545	A1	19900813	AU 1990-49545	19900110
	AU 638693	B2	19930708		
	ZA 9000171	A	19901128	ZA 1990-171	19900110
	EP 453497	A1	19911030	EP 1990-902445	19900110
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	BR 9007016	A	19911112	BR 1990-7016	19900110
	JP 04502621	T2	19920514	JP 1990-502474	19900110
	HU 62487	A2	19930528	HU 1991-2326	19900110
PRAI	US 1989-295454		19890110		
	US 1989-364063		19890608		

=> d ab 4-8 111

L11 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2000 ACS

AB A method of using receptor-mediated endocytosis to increase the efficiency

of DNA uptake by eukaryotic cells is described. The method uses fusion proteins of **receptor-binding** domains of toxins, therefore lacking the domains necessary for toxic activity, and **DNA-binding** domains. These fusion proteins are taken up by the receptor for the toxin and the DNA it is bound to is incorporated into the endosome. When the endosome is internalized, the complex is released and the protein stripped from the DNA leaving it free to become part of the host cell genome. A fusion protein of the heat-labile enterotoxin of *Escherichia coli* and the histone H1-like protein of *Bordetella pertussis* was prepd. by expression of the cloned gene. The protein was shown to retain **DNA binding** activity.

Similarly, a fusion protein of diphtheria toxin and GAL4 was shown to have

DNA binding and to retain the normal binding of the toxin to Vero cells. The fusion protein was also rapidly internalized by Vero cells.

L11 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2000 ACS

AB A compn. comprising a GM1-binding protein and a polynucleotide in assocn. with the binding protein is described for delivery of a polynucleotide to mucosal, neural, or other cells. A method is described for modulating immunity comprising administering the compn. to an animal and expressing the polynucleotide whereby the animal generates an immune response to the product of the polynucleotide. Also included is a method for gene therapy

comprising administering to an animal a GM1-binding protein and a functional polynucleotide and expressing the polynucleotide in the animal whereby the function of the polynucleotide confers on the animal a therapeutic effect.

L11 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2000 ACS

AB The invention features purified nucleic acids that encode hepadnavirus cellular receptors. One receptor is a 170 kD cell surface glycoprotein, referred to as the p170 receptor. Parts of the p170 sequence are similar to that of basic carboxypeptidase. The pre-S domain of the duck hepatitis

B virus envelope protein binds the p170 receptor at a major neutralizing epitope (amino acids 87-102), within which are two basic amino acids (Lys-95, Arg-97) required for virion-receptor interaction. A 46-amino acid pre-S protein covering this binding site inhibits duck hepatitis B virus infection of primary duck hepatocytes. An addnl. pre-S binding protein of 120-kilodaltons (p120) was identified. P120 was identified as glycine decarboxylase. Its role as part of the viral receptor complex

was

suggested by its restricted expression in duck hepatitis B virus-infectible tissues, by co-localization of its binding site with three virus neutralizing epitopes, and by markedly decreased infectivity of duck hepatitis B virus mutants constructed with impaired p120 binding motif.

L11 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2000 ACS

AB The invention features a polypeptide consisting of amino acids 379-535 of diphtheria toxin, and portions thereof. This region, shown by X-ray crystallog. anal. to comprise the **receptor binding** domain of diphtheria toxin, is useful for a **vaccine** and as a

therapeutic against alzheimeria (no therapeutic data).

L11 ANSWER 8 OF 10 PLUS COPYRIGHT 2000 ACS

AB Methods are provided for treatment of virus-infected patients using a photoactive compd. (e.g. psoralen or a psoralen deriv.) that, upon activation by exposure to electromagnetic radiation of a prescribed spectrum (e.g. UV light), inactivates and/or attenuates the virus and permits the treated virus and/or virus-infected cells to be presented to the patient's immune system. Medicaments and a photophoresis app. for carrying out the methods of the invention are also provided. Thus, patients with AIDS or AIDS-related complex were administered 8-methoxypsoralen and treated by photophoresis. Changes in levels of antibodies to Gp24 and Gp120, as well as CD4 helper cell percentages, are presented.